{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:13:09Z","timestamp":1788865989853,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Grant-in-Aid for Science Research from the Japanese Osteoporosis Society"},{"DOI":"10.13039\/501100004206","name":"The University of Osaka","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00198-026-08051-0","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:15:49Z","timestamp":1778217349000},"page":"1247-1256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of oral glucocorticoids on the effectiveness of romosozumab: the multicenter OASIS cohort study"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2265-6724","authenticated-orcid":false,"given":"Toshitaka","family":"Yukishima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6814-9920","authenticated-orcid":false,"given":"Tomonori","family":"Kobayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0422-8139","authenticated-orcid":false,"given":"Yuji","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Kanayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2001-0674","authenticated-orcid":false,"given":"Rui","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5741-5969","authenticated-orcid":false,"given":"Yuki","family":"Etani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9938-6780","authenticated-orcid":false,"given":"Takaaki","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-5501","authenticated-orcid":false,"given":"Taiji","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3496-3956","authenticated-orcid":false,"given":"Kumiko","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6792-8458","authenticated-orcid":false,"given":"Yuichiro","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6888-0698","authenticated-orcid":false,"given":"Toshiyuki","family":"Ojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-4984","authenticated-orcid":false,"given":"Ken","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5107-8209","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1024","authenticated-orcid":false,"given":"Kosuke","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"8051_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","volume":"61","author":"J Compston","year":"2018","unstructured":"Compston J (2018) Glucocorticoid-induced osteoporosis: an update. Endocrine 61:7\u201316","journal-title":"Endocrine"},{"key":"8051_CR2","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Van Staa","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993\u20131000","journal-title":"J Bone Miner Res"},{"key":"8051_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMcp1012926","volume":"365","author":"RS Weinstein","year":"2011","unstructured":"Weinstein RS (2011) Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 365:62\u201370","journal-title":"N Engl J Med"},{"key":"8051_CR4","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319\u201328","journal-title":"Osteoporos Int"},{"key":"8051_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.bone.2013.08.016","volume":"57","author":"L Gifre","year":"2013","unstructured":"Gifre L, Ruiz-Gaspa S, Monegal A et al (2013) Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 57:272\u2013276","journal-title":"Bone"},{"key":"8051_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326","journal-title":"J Bone Miner Res"},{"key":"8051_CR7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"8051_CR8","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or Alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u201327","journal-title":"N Engl J Med"},{"key":"8051_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/mr\/roac014","volume":"33","author":"T Kobayakawa","year":"2023","unstructured":"Kobayakawa T, Miyazaki A, Kanayama Y et al (2023) Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration. Mod Rheumatol 33:96\u2013103","journal-title":"Mod Rheumatol"},{"key":"8051_CR10","doi-asserted-by":"publisher","first-page":"e2778","DOI":"10.1210\/clinem\/dgae810","volume":"110","author":"M Kawazoe","year":"2025","unstructured":"Kawazoe M, Kaneko K, Masuoka S et al (2025) Comparison of efficacy of Romosozumab with Denosumab and Risedronate in patients newly initiating glucocorticoid therapy. J Clin Endocrinol Metab 110:e2778\u2013e2786","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"8051_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keag082","volume":"65","author":"T Yukishima","year":"2026","unstructured":"Yukishima T, Kobayakawa T, Hirano Y et al (2026) Effectiveness of denosumab, teriparatide, and romosozumab for glucocorticoid-induced osteoporosis: a propensity score-matched cohort study. Rheumatology (Oxford) 65(3):keag082","journal-title":"Rheumatology (Oxford)"},{"key":"8051_CR12","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","volume":"23","author":"A Diez-Perez","year":"2012","unstructured":"Diez-Perez A, Adachi JD, Agnusdei D et al (2012) Treatment failure in osteoporosis. Osteoporos Int 23:2769\u20132774","journal-title":"Osteoporos Int"},{"key":"8051_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo H, Nakamura T, Hosoi T et al (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2013executive summary. Arch Osteoporos 7:3\u201320","journal-title":"Arch Osteoporos"},{"key":"8051_CR14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"8051_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00198-025-07386-4","volume":"36","author":"T Yukishima","year":"2025","unstructured":"Yukishima T, Ebina K, Etani Y et al (2025) Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case-control study. Osteoporos Int 36:531\u2013538","journal-title":"Osteoporos Int"},{"key":"8051_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00774-024-01502-w","volume":"42","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, Soen S, Hirata S et al (2024) The 2023 guidelines for the management and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Metab 42:143\u2013154","journal-title":"J Bone Miner Metab"},{"key":"8051_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jocd.2016.03.003","volume":"19","author":"EM Lewiecki","year":"2016","unstructured":"Lewiecki EM, Binkley N, Morgan SL et al (2016) Best Practices for Dual-Energy X-ray Absorptiometry Measurement and Reporting: International Society for Clinical Densitometry Guidance. J Clin Densitom 19:127\u2013140","journal-title":"J Clin Densitom"},{"key":"8051_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0962280210394483","volume":"21","author":"E Williamson","year":"2012","unstructured":"Williamson E, Morley R, Lucas A, Carpenter J (2012) Propensity scores: from naive enthusiasm to intuitive understanding. Stat Methods Med Res 21:273\u2013293","journal-title":"Stat Methods Med Res"},{"key":"8051_CR19","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083\u20133107","journal-title":"Stat Med"},{"key":"8051_CR20","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1007\/s00198-022-06545-1","volume":"33","author":"K Ebina","year":"2022","unstructured":"Ebina K, Etani Y, Tsuboi H et al (2022) Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis. Osteoporos Int 33:2441\u20133","journal-title":"Osteoporos Int"},{"key":"8051_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u201320","journal-title":"N Engl J Med"},{"key":"8051_CR22","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65\u201370","journal-title":"Scand J Stat"},{"key":"8051_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone 96:29\u201337","journal-title":"Bone"},{"key":"8051_CR24","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1056\/NEJMra053077","volume":"354","author":"E Seeman","year":"2006","unstructured":"Seeman E, Delmas PD (2006) Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med 354:2250\u20132261","journal-title":"N Engl J Med"},{"key":"8051_CR25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev.bioeng.8.061505.095721","volume":"8","author":"AG Robling","year":"2006","unstructured":"Robling AG, Castillo AB, Turner CH (2006) Biomechanical and molecular regulation of bone remodeling. Annu Rev Biomed Eng 8:455\u2013498","journal-title":"Annu Rev Biomed Eng"},{"key":"8051_CR26","first-page":"119","volume":"67","author":"E Lespessailles","year":"2000","unstructured":"Lespessailles E, Poupon S, Adriambelosoa N et al (2000) Glucocorticoid-induced osteoporosis: is the bone density decrease the only explanation? Joint Bone Spine 67:119\u2013126","journal-title":"Joint Bone Spine"},{"key":"8051_CR27","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809\u2013816","journal-title":"Osteoporos Int"},{"key":"8051_CR28","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.bone.2009.06.030","volume":"46","author":"RS Weinstein","year":"2010","unstructured":"Weinstein RS (2010) Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity. Bone 46:564\u2013570","journal-title":"Bone"},{"key":"8051_CR29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S8756-3282(01)00610-X","volume":"29","author":"D Patschan","year":"2001","unstructured":"Patschan D, Loddenkemper K, Buttgereit F (2001) Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 29:498\u2013505","journal-title":"Bone"},{"key":"8051_CR30","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/art.39183","volume":"67","author":"N Yeremenko","year":"2015","unstructured":"Yeremenko N, Zwerina K, Rigter G et al (2015) Tumor necrosis factor and interleukin-6 differentially regulate Dkk-1 in the inflamed arthritic joint. Arthritis Rheumatol 67:2071\u20132075","journal-title":"Arthritis Rheumatol"},{"key":"8051_CR31","first-page":"921","volume":"29","author":"E Terpos","year":"2011","unstructured":"Terpos E, Fragiadaki K, Konsta M, Bratengeier C, Papatheodorou A, Sfikakis PP (2011) Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol 29:921\u2013925","journal-title":"Clin Exp Rheumatol"},{"key":"8051_CR32","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s00774-013-0514-1","volume":"32","author":"S Kaneshiro","year":"2014","unstructured":"Kaneshiro S, Ebina K, Shi K et al (2014) IL-6 negatively regulates osteoblast differentiation through the SHP2\/MEK2 and SHP2\/Akt2 pathways in vitro. J Bone Miner Metab 32:378\u2013392","journal-title":"J Bone Miner Metab"},{"key":"8051_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/ar4180","volume":"15","author":"D Aeberli","year":"2013","unstructured":"Aeberli D, Schett G (2013) Cortical remodeling during menopause, rheumatoid arthritis, glucocorticoid and bisphosphonate therapy. Arthritis Res Ther 15:208","journal-title":"Arthritis Res Ther"},{"key":"8051_CR34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00198-024-07019-2","volume":"35","author":"K Ebina","year":"2024","unstructured":"Ebina K, Nagayama Y, Kashii M et al (2024) An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study. Osteoporos Int 35:841\u2013849","journal-title":"Osteoporos Int"},{"key":"8051_CR35","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/jbmr.3036","volume":"32","author":"MS Ominsky","year":"2017","unstructured":"Ominsky MS, Boyd SK, Varela A et al (2017) Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res 32:788\u2013801","journal-title":"J Bone Miner Res"},{"key":"8051_CR36","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1002\/jbmr.2855","volume":"31","author":"R Zebaze","year":"2016","unstructured":"Zebaze R, Libanati C, McClung MR et al (2016) Denosumab reduces cortical porosity of the proximal femoral shaft in postmenopausal women with osteoporosis. J Bone Miner Res 31:1827\u20131834","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08051-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08051-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08051-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:03:56Z","timestamp":1788865436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-08051-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["8051"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08051-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KE has received research grants from Asahi-Kasei and Teijin Pharma. KE has received payments for lectures from AbbVie, Amgen, Asahi-Kasei, Astellas, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Ono, Pfizer, Taisho, Tanabe-Mitsubishi, and Teijin Pharma. KE holds an additional post of the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi-Kasei. TK has received payments for lectures from Amgen, Asahi-Kasei, Daiichi Sankyo, Eli Lilly, and Teijin Pharma. YH has received payments for lectures from AbbVie, Amgen, Asahi-Kasei, Astellas, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Taisho, Tanabe-Mitsubishi, and Teijin Pharma. YK has received payments for lectures from AbbVie, Amgen, Asahi-Kasei, Astellas, Daiichi Sankyo, Eisai, Eli Lilly, Gilead and Taisho. RN has received payments for lectures from Amgen, Asahi-Kasei, Astellas, and Teijin Pharma. YE has received research grants and\/or speaker fees from Asahi-Kasei, Eisai, Eli Lilly, Mitsubishi Tanabe, Ono Pharma, and Taisho. YE is affiliated with the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi-Kasei. KN supervises the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi-Kasei. TY, TN, TN, KS, YM, TO and SO declare that they have no conflicts of interest.","order":2,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}]}}